The agreement grants Lupin exclusive rights to promote, distribute and market Zaxine in Canada
Lupin’s Canadian subsidiary, Lupin Pharma Canada (collectively Lupin) has launched its first Brand product Zaxine under a strategic licensing agreement with the North Carolina-based GI speciality company Salix Pharmaceuticals. The agreement grants Lupin exclusive rights to promote, distribute and market Zaxine in Canada.
Zaxine 550mg (rifaximin) is a long-term antibiotic treatment for adults living with hepatic encephalopathy (HE), a complication of liver disease (cirrhosis). HE can lead to a wide spectrum of mental and physical symptoms, including confusion, disruption in sleep patterns, personality changes and coma Zaxine 550mg has approved by Health Canada under priority review for the reduction in risk of overt HE recurrence in patients ≥ 18 year of age.
Lupin will promote the product to hepatologists and gastroenterologists through its own specialty sales force in Canada. Lupin is in the process of establishing its Canadian presence and the launch opens up growth opportunities for the future. Zaxine is a ‘First-in-Class’ treatment for HE that currently has limited options for long term treatment.
Vinita Gupta, Chief Executive Officer, Lupin said, “We are excited with the expansion of Lupin’s business into Canada given the opportunity we have, to create a brand presence with the launch of Zaxine. The launch demonstrates Lupin’s commitment to grow its brand franchise in North America and bring meaningful products to patients in Canada.”
Comments are closed.